Elevated production of BAFF by NK cells following rituximab treatment (anti-CD20 antibody) impairs NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC), causing CLL resistance [210]. Here, TNFSF13B is linked to B-cell chronic lymphocytic leukemia.